The study participants are female patients with breast cancer receiving Anthracycline based chemotherapy.~They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo.~Full echocardiographic study including 3D echocardiography will be done to all patients before starting their chemotherapy and after 6 months.
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity